Current concepts in radiation enteritis and implications for future clinical trials
โ Scribed by Nam P. Nguyen; John E. Antoine; Suresh Dutta; Ulf Karlsson; Sabah Sallah
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 126 KB
- Volume
- 95
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
Background:
Radiation enteritis is one of the most feared complications of abdominal and pelvic radiation. once its occurs, the process is relentless and may result in the patient's death. available treatment is only supportive. recent progress in molecular biology has shed some light on the pathogenesis of radiation enteritis and other diseases that are characterized by excessive fibrosis. new treatment modalities may be devised to improve the outcome of patients who are affected with this complication.
Methods:
A literature search was used to identify the common denominator between many radiation-induced fibrotic conditions and other sclerotic diseases. factors that affect the disease process and possible therapeutic interventions were evaluated.
Results:
The hyperstimulation of transforming growth factor beta1 (tgf-beta1) leads to increased fibrosis and, ultimately, organ failure. interferon gamma (ifn-gamma) inhibits the effects of tgf-beta1 in the nucleus. the fibrotic process may be reverted by ifn-gamma in various pathologic conditions.
Conclusions:
Radiation enteritis and other radiation-induced, long-term complications are characterized by excessive stimulation of tgf-beta1. preliminary studies suggest that ifn-gamma may be effective in the treatment of patients with radiation-induced cutaneous fibrosis. ifn-gamma should be considered in phase i-ii studies to assess its toxicity and efficacy in the treatment of patients with radiation enteritis.
๐ SIMILAR VOLUMES
Context -Genetics services are not well integrated into the public health programs of most states, nor has there been effective use of clinical and program databases in the design, evaluation, and monitoring of public health genetics services at the state level. Objective -To evaluate the availabili
Response-guided pegylated interferon (peg-IFN) plus ribavirin (P/R) therapy trials on genotype (G)1 and G2/G3 hepatitis C virus-infected patients provide contradictory results. We conducted meta-analyses of randomized, controlled trials to address (1) the benefit of a 72-week extended-duration thera